Brief: Stayble Therapeutics Phase IIB Study Does Not Meet Primary Endpoint

Stayble Therapeutics AB

05/01/2024 11:59

Jan 5 (Reuters) - Stayble Therapeutics AB  STABL.ST :
    * IN LINE WITH PREVIOUSLY ANNOUNCED PRELIM RESULTS, THE
PHASE IIB
STUDY  AGAINST CHRONIC DISC-RELATED BACK PAIN DID NOT MEET
PRIMARY ENDPOINT

Source text for Eikon:  ID:nWkr1H51X 
Further company coverage:  STABL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))